Therapeutic potential of iron chelators in cancer therapy

Advances in Experimental Medicine and Biology

Volumn 509, Issue , 2003, Pages 231-249

  Richardson, Des R ^a  

^a HEART RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXY 1 NAPHTHYLALDEHYDE ISONICOTINOYLHYDRAZONE; 3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; 5 HYDROXYPICOLINALDEHYDE THIOSEMICARBAZONE; DEFEROXAMINE; HYDRAZONE DERIVATIVE; IRON CHELATING AGENT; PYRIDOXAL ISONICOTINOYLHYDRAZONE; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; IRON; ISONIAZID; PROTEIN P53; PYRIDOXAL; PYRIDOXAL ISONICOTINOYL HYDRAZONE;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER GROWTH; CANCER THERAPY; CELL CYCLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HALF LIFE; HUMAN; HUMAN CELL; IRON METABOLISM; LEUKEMIA; MEMBRANE PERMEABILITY; NEUROBLASTOMA; PRIORITY JOURNAL; REVIEW; ANIMAL; DRUG EFFECT; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; DEFEROXAMINE; HUMANS; IRON; IRON CHELATING AGENTS; ISONIAZID; NEOPLASMS; PYRIDOXAL; THIOSEMICARBAZONES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0041308109     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (105)

1. Olivieri, N.F., and Brittenham, G.M., 1997, Iron chelating therapy and the treatment of thalassemia, Blood 89:739.
2. Richardson, D.R., and Ponka, P., 1998, The development of iron chelators to treat iron overload disease and their use as experimental tools to study intracellular iron metabolism, Am. J. Hematol. 58:299.
3. Donfrancesco, A., Deb, G., De Sio, L., Cozza, R., and Castellano, A., 1996, Role of desferrioxamine in tumor therapy, Acta Haematol. 95:66.
4. Richardson, D.R., 1997, Iron chelators as effective anti-proliferative agents, Can. J. Physiol. Pharmacol. 75:1164.
5. Hentze, M.W., and Kuhn, L.C., 1996, Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress, Proc. Natl. Acad. Sci. USA, 93:8175.
6. Richardson, D.R., and Ponka, P., 1997, The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells, Biochim. Biophys. Acta 1331:1.
7. Ponka, P., Beaumont, C., and Richardson, D.R., 1998, Function and regulation of transferrin and ferritin, Semin Hematol. 35:35.
8. Myers, C., Gianni, L., Zweier, J., Muindi, J., Sinha, K., and Eliot T., 1986, Role of iron in adriamycin biochemistry, Fed. Proc. 45:2792.
9. Kwok, J., and Richardson, D.R., 2000, The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity, Redox Report 6: (in press)
10. Burger, R.M., Peisach, J., and Horwitz, S.B. 1981, Activated bleomycin: a transient complex of drug, iron and oxygen that degrades DNA, J. Biol. Chem. 256:11636.
11. Salmon, S.E., Part VII, 1980, Chemotherapeutic Agents-Cancer Chemotherapy. In: Meyers, F.H., Jawetz, E., Goldfien, E., Goldfien, A., eds. Review of Medical Pharmacology. Los Altos: Lange Medical Publications, 477.
12. Nyholm, S., Thelander, L., and Graslund, A., 1993, Reduction and loss of the iron center in the reaction of the small subunit of mouse ribonucleotide reductase with hydroxyurea, Biochemistry 32:11569.
13. Nyholm, S., Mann, G.J., Johansson, A.G., Bergeron, R.J., Graslund, A., and Thelander, L., 1993, Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators, J. Biol. Chem. 268: 26200.
14. Cooper, C.E., Lynagh, G.R., Hoyes, K.P., Hider, R.C., Cammack, R., and Porter, J.B. 1996, The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J. Biol. Chem. 271:20291.
15. Richardson, D.R., Tran, E., and Ponka, P., 1995, The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, Blood 86:4295.
16. Richardson, D.R., and Milnes, K., 1997, The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents II: The mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone, Blood 89:3025.
17. Finch, R.A., Liu, M-C., Grill, S.P., Rose, W.C., Loomis, R., Vasquez, K.M., Cheng, Y-C., and Sartorelli, A.C., 2000, Triapine (3-aminopyridine-2- carboxaldehyde-thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity, Biochem. Pharmacol. 59:983.
18. Beckloff, G.L., Lerner, H.J., Frost, D., Russo-Alesi, F.M., and Gitomer, S., 1965, Hydroxyurea (NSC-32065) in biological fluids: Dose-concentration relationship, Cancer Chemother. Rep. 48:57.
19. Gwilt, P.R., and Tracewell, W.G., 1998, Pharmacokinetics and pharmacodynamics of hydroxyurea, Clin. Pharmacokinet. 34:347.
20. Moore, E.G., and Hurlbert, R.B., 1989, The inhibition of ribonucleoside diphosphate reductase by hydroxyurea, guanazole and pyrazoloimidazole (IMPY). In: Inhibitors of Ribonucleoside Diphosphate Reductase Activity, Cory, J.G., Cory, A.H., eds., Pergamon Press, Oxford, pp. 165-201.
21. Darnell, G., and Richardson, D.R., 1999, The potential of analogues of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents III: The effect of the ligands on molecular targets involved in proliferation, Blood 94:781.
22. Chitambar, C.R., and Wereley, J., 1995, Effect of hydroxyurea on cellular iron metabolism in human leukemic CCRF-CEM cells: Changes in iron uptake and the regulation of transferrin receptor and ferritin gene expression following inhibition of DNA synthesis, Cancer Res. 55:4361.
23. 1 phase of the cell cycle, Cancer Res. 53:3968.
24. rd Edn., Churchill Livingston Publishers.
25. Blatt, J., and Stitely, S., 1987, Antineuroblastoma activity of desferrioxamine in human cell lines, Cancer Res. 47:1749.
26. Becton, D.L., and Bryles, P., 1988, Deferoxamine inhibition of human neuroblastoma viability and proliferation, Cancer Res. 48:7189.
27. Donfrancesco, A., Deb, G., Dominici, C., Pileggi, D., Castello, M.A., and Helson, L., 1990, Effects of a single course of deferoxamine in neuroblastoma patients, Cancer Res. 50:4929.
28. Kontoghiorghes, G.J., and Evans, R.W. 1985, Site specificity of iron removal from transferrin by α-ketohydroxypyridone chelators, FEBS Lett. 189:141.
29. Baker, E., Richardson, D.R., Gross, S., and Ponka, P., 1992, Evaluation of the iron chelation potential of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture, Hepatology, 15:492.
30. Morgan, E.H., 1981, Transferrin: biochemistry, physiology and clinical significance, Mol. Aspects Med. 4:1.
31. Kawabata, H., Yang, R., Hirama, T., Vuong, P.T., Kawano, S., Gombart, A.F., and Koeffler, H.P., 1999, Molecular cloning of transferrin receptor 2: A new member of the transferrin receptor-like family, J. Biol. Chem. 274:20826.
32. Kawabata, H., Germain, R.S., Vuong, P.T., Nakamaki, T., Said, J.W., and Koeffler, H.P., 2000, Transferrin receptor 2-α supports cell growth both in iron-chelated cultured cells and in vivo, J. Biol. Chem. 275:16618.
33. Page, M.A., Baker, E., and Morgan, E.H., 1984, Transferrin and iron uptake by rat hepatocytes in culture, Am. J. Physiol. 246:G26.
34. Trinder, D., Morgan, E.H., and Baker, E., 1986, The mechanisms of iron uptake by rat fetal hepatocytes, Hepatology 6:852.
35. Richardson, D.R., and Baker, E., 1990, The uptake of iron and transferrin by the human melanoma cell, Biochim Biophys. Acta 1053:1.
36. Richardson, D.R., and Baker, E., 1994, Two saturable mechanisms of iron uptake from transferrin in human melanoma cells: The effect of transferrin concentration, chelators and metabolic probes on transferrin and iron uptake, J. Cell Physiol. 161:160.
37. Richardson, D.R., and Ponka, P., 1994, The iron metabolism of the human neuroblastoma cell. Lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis, J. Lab. Clin. Med. 124:660.
38. Trinder, D., Zak, O., and Aisen, P., 1996, Transferrin receptor-independent uptake of diferric transferrin by human hepatoma cells with antisense inhibition of receptor expression, Hepatology 23:1512.
39. Trowbridge, I.S., and Lopez, F., 1982, Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits tumor cell growth in vitro, Proc. Natl. Acad. Sci. USA 79:1175.
40. Kemp, J.D., Smith, K.M., Kanner, L.J., Gomez, F., Thorson, J.A., and Naumann, P.W., 1990, Synergistic inhibition of lymphoid tumor growth in vitro by combined treatment with the iron chelator deferoxamine and an immunoglobulin G monoclonal antibody against the transferrin receptor, Blood 76:991.
41. Kemp, J.D., Thorson, J.A., Stewart, B.C., and Naumann, P.W., 1992, Inhibition of hematopoietic tumor growth by combined treatment with deferoxamine and an IgG monoclonal antibody against the transferrin receptor: evidence for a threshold model of iron deprivation toxicity, Cancer Res. 52:4144.
42. Levy, J.E., Jin, O., Fujiwara, Y., Kuo, F., and Andrews, N.C., 1999, Transferrin receptor is necessary for the development of erythrocytes and the nervous system, Nature Genet. 21:396.
43. Chan, L-N.L., and Gerhardt, E.M., 1992, Transferrin receptor gene is hyperexpressed and transcriptionally regulated in differentiating erythroid cells, J. Biol. Chem. 267:8254.
44. Bianchi, L., Tacchini, L., and Cairo, G., 1999, HIF-1-mediated activation of transferrin receptor gene transcription by iron chelation, Nucleic Acids Res. 27:4223.
45. Lok, C.N., and Ponka, P., 1999, Identification of a hypoxia response element in the transferrin receptor gene. J. Biol. Chem. 274:24147.
46. Tacchini, L., Bianchi, L., Bernelli-Zazzera, A., and Cairo, G., 1999, Transferrin receptor induction by hypoxia. HIF-1 mediated transcriptional activation and cell specific post-transcriptional regulation, J. Biol. Chem. 274:24142.
47. Larrick, J.W., and Cresswell, P., 1979, Modulation of cell surface iron transferrin receptors by cellular density and the state of activation, J. Supramol. Struct. 11:579.
48. Richardson, D.R., and Baker, E., 1992, Two mechanisms of iron uptake from transferrin by melanoma cells. The effect of desferrioxamine and ferric ammonium citrate, J. Biol. Chem. 267:13972.
49. Chan, S.M., Hoffer, P.B., Maric, N., and Duray, P., 1987, Inhibition of gallium-67 uptake in melanoma by an anti-human transferrin receptor monoclonal antibody, J. Nucl. Med. 28:1303.
50. Crawford, E.D., Saiers, J.H., Baker, L.H., Costanzi, J.H., and Bukowski, R.M., 1991, Gallium nitrate in advanced bladder carcinoma: southwest oncology group study, Urology, 38:355.
51. Chitambar, C.R., Zahir, S.A., Ritch, P.S., and Anderson, T., 1997, Evaluation of continuous-infusion gallium nitrate and hydroxyurea in combination for the treatment of refractory non-Hodgkin's lymphoma, Am. J. Clin. Oncol. 20:173.
52. Chitamber, C.R. and Seligman, P.A., 1986, Effects of different transferrin forms on transferrin receptor expression, iron uptake, and cellular proliferation of human leukemic HL60 cells: mechanisms responsible for the specific cytotoxicity of transferrin-gallium, J. Clin. Invest. 78: 1538.
53. Chitambar, C.R., and Zivkovic, Z., 1987, Uptake of gallium-67 by human leukemic cells: Demonstration of transferrin receptor-dependent and transferrin receptor-independent mechanisms, Cancer Res. 47:3929.
54. Lovejoy, D.B., and Richardson, D.R., 2000, Complexes of gallium(III) and other metal ions and their potential in the treatment of neoplasia, Expert Opin. Invest. Drugs 9:1257.
55. Gunshin, H., MacKenzie, B., Berger, U.V., Gunshin, Y., Romero, M.F., Boron, W.F., Nussberger, S., Gollan, J.L., and Hediger, M.A., 1997, Cloning and characterization of a mammalian proton-coupled metal-ion transporter, Nature 388:482.
56. Fleming, M.D., Trenor, C.C., Su, M.A., Foernzler, D., Beier, D.R., Dietrich, W.F., and Andrews, N.C., 1997, Microcytic anemia mice have a mutation in Nramp2, a candidate iron transporter gene, Nat. Genet. 16:383.
57. Harrison, P.M., and Arosio, P., 1996, The ferritins: molecular properties, iron storage function and cellular regulation, Biochim. Biophys. Acta 1275:161.
58. Osaki, S., Johnson, D.A., and Frieden, E., 1971, The mobilization of iron from the perfused mammalian liver by a serum copper enzyme, ferroxidase I, J. Biol. Chem. 246:3018.
59. Young, S.P., Fahmy, M., and Golding, S., 1997, Ceruloplasmin, transferrin and apotransferrin facilitate iron release from human liver cells, FEBS Lett. 411:93.
60. Richardson, D.R., 1999, The role of ceruloplasmin and ascorbate in cellular iron release, J. Lab. Clin. Med. 134:454.
61. Donovan, A., Brownlie, A., Zhou, Y., Shepard, J., Pratt, S.J., Moynihan, J., Paw, B.H., Drejer, A., Barut, B., Zapata, A., Law, T.C., Brugnara, C., Lux, S.E., Pinkus, G.S., Pinkus, J.L., Kingsley, P.D., Palis, J., Fleming, M.D., Andrews, N.C., and Zon, L.I., 2000, Positional cloning of zebrafish ferroportin I identifies a conserved vertebrate iron exporter, Nature 403:776.
62. Estrov, Z., Tawa, A., Wang, X-H., Dube, I.D., Sulh, H., Cohen, A., Gelfand, E.W., and Freedman, M.H., 1987, In vivo and in vitro effects of desferrioxamine in neonatal acute leukemia, Blood 69:757.
63. Dezza, L., Cazzola, M., Danova, M., Carlo-Stella, C., Bergamaschi, G., Brugnatelli, S., Invernizzi, R., Mazzini, G., Riccardi, A., and Ascari, E., 1989, Effects of desferrioxamine on normal and leukemic human hematopoietic cell growth: in vitro and in vivo studies, Leukemia 3:104.
64. Donfrancesco, A., Deb, G., Dominici, C., Angioni, A., Caniglia, M., De Sio, L., Fidani, P., Amici, A., and Helson, L., 1992, Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECat): A new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma, Am. J. Clin. Oncol. 15:319.
65. Donfrancesco, A., De Bernardi, B., Carli, M., Mancini, A., Nigro, M., De Sio, L., Casale, F., Bagnulo, S., Helson, L., and Deb, G., 1995, Deferoxamine (D) followed by cytoxan (C), etoposide (E), carboplatin (Ca), thio-TEPA (T), induction regimen in advanced neuroblastoma, Eur. J. Cancer 31A:612.
66. Richardson, D.R., 1998, Analogues of pyridoxal isonicotinoyl hydrazone (PIH) as potential iron chelators for the treatment of neoplasia, Leukemia & Lymphoma 31:47.
67. Richardson, D.R., 2001, The use of iron chelators as therapeutic agents for the treatment of cancer, Crit. Rev. Oncol. Hematol. (in press).
68. Voute, P.A., 1984, Neuroblastoma, In: Clinical Pediatric Oncology, Mosby Publ. Co., 1984:559.
69. Selig, R.A., White, L., Gramacho, C., Sterlinglevis, K., Fraser, I.W., and Naidoo, D., 1998, Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts, Cancer Res. 58:473.
70. Blatt, J., 1994, Deferoxamine in children with recurrent neuroblastoma, Anticancer Res. 14:2109.
71. Sartorelli, A.C., Agrawal, K.C., and Moore, E.C., 1971, Mechanism of inhibition of ribonucleoside diphosphate reductase by α-(N)-heterocyclic aldehyde thiosemicarbazones, Biochem. Pharmacol. 20:3119.
72. French, F.A., Blanz, E.J. J.R., Schaddix, S.C., and Brockman, R.W., 1974, α-(N)-Formylheteroaromatic thiosemicarbazones. Inhibition of tumor derived ribonucleoside diphosphate reductase and correlation with in vivo anti-tumor activity, J. Med. Chem. 17:172.
73. Liu, M-C., Lin, T-S., and Sartorelli, A.C., 1995, Chemical and biological properties of cytotoxic α-(N)-heterocyclic carboxaldehyde thiosemicarbazones. In: Progress in Medicinal Chemistry, Volume 32. Ellis, G.P., Luscombe, D.K. (Eds.), Elsevier Science B.V. 1-35.
74. Agrawal, K.C., and Sartorelli, A.C., 1978, The chemistry and biological activity of α-(N)-heterocyclic carboxaldehyde thiosemicarbazones, Prog. Med. Chem. 15:321.
75. DeConti, R.C., Toftness, B.R., Agrawal, K.C., Tomchick, R., Mead, J.A.R., Bertino, J.R., Sartorelli, A.C., and Creasey, W.A., 1972, Clinical and pharmacological studies with 5-hydroxy-2-formylpyridine thiosemicarbazone, Cancer Res. 32:1455.
76. Krakoff, I.H., Etcubanas, E., Tan, C., Mayer, K., Bethune, V., and Burchenai, J.H., 1974, Clinical trial of 5-hydroxypicolinaldehyde thiosemicarbazone (5-HP: NSC-107392), with special reference to its Fe chelating properties, Cancer Chemother. Rep. 53:207.
77. Sah, P., 1954, Nicotinoyl and isonicotinoyl hydrazones of pyridoxal, J. Am. Chem. Soc., 76:300.
78. Ponka, P., Borova, J., Neuwirt, J., and Fuchs, O., 1979, Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent, FEBS Lett. 97:317.
79. Ponka, P., Borova, J, Neuwirt, J., Fuchs, O., and Necas, E., 1979, A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents, Biochim. Biophys. Acta 586:278.
80. Cikrt, M., Ponka, P., Necas, E., and Neuwirt, J., 1980, Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone, Br. J. Haematol. 45:275.
81. Hoy, T., Humphreys, J., Jacobs, A., Williams, A., and Ponka, P., 1979, Effective iron chelation following oral adminstration of an isoniazid pyridoxal hydrazone, Br. J. Haematol. 43:443.
82. Baker, E., Vitolo, M.L., and Webb, J.M., 1985, Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture, Biochem. Pharmacol. 34:3011.
83. Richardson, D.R., and Ponka, P., 1998, Orally effective iron chelators for the treatment of iron overload disease: The case for a further look at pyridoxal isonicotinoyl hydrazone (PIH) and its analogs, J. Lab. Clin. Med. 132:351.
84. Brittenham, G.M., 1990, Pyridoxal isonicotinoyl hydrazone: an effective chelator after oral administration, Semin. Hematol. 27:112.
85. Hoyes, K.P., Hider, R.C., and Porter, J.B., 1992, Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemic cell lines. Cancer Res. 52:4591.
86. Lucas, J.J., Terada, N., Szepesi, A., and Gelfand, E.W., 1992, Regulation of synthesis of p34cdc2 and its homologues and their relationship to p110Rb phosphorylation during cell cycle progression of normal human T cells, J. Immunol. 148:1804.
87. Agarwal, M.L., Taylor W.R., Chernov M.V., Chernova O.B., and Stark, G.R., 1998, The p53 network, J. Biol. Chem. 273:1.
88. Greenblatt, M.S., Bennett, W.P., Hollstein, and M., Harris, C.C., 1994, Mutations in the p53 suppressor gene: clues to cancer etiology and molecular pathogenesis, Cancer Res. 54:4855.
89. Xiong, Y., Hannon, G.J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D., 1993, p21 is a universal inhibitor of cyclin kinases, Nature 366:701.
90. Levine, A.J., 1997, p53, the cellular gatekeeper for growth and division, Cell 88:323.
91. Katan, M.B., Zhan, Q., El-Deiry, W.S., Carrier, F., Jacks, T., Walsh, W.V., Plunkett, B.S., Vogelstein, B., and Fornace, A.J. Jr, 1992, A mammalian cell cycle check point pathway utilizing p53 and gadd45 is defective in ataxia telangiectasia, Cell 71:587.
92. Tanaka, H., Arakawa, H., Yamaguchi, T., Shiraishi, K., Fukuda, S., Matsui, K., Takei, Y., and Nakamura, Y., 2000, A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage, Nature 404:42.
93. Terada, N., Lucas, J.J., and Gelfand, E.W., 1991, Differential regulation of the tumor suppressor molecules, retinoblastoma susceptibility gene product (Rb) and p53, during cell cycle progression of normal human T cells, J. Immunol. 147:698.
94. Fukuchi, K., Tomoyasu, S., Watanabe, H., Kaetsu, S., Tsuruoka, N., and Gomi, K., 1995, Iron deprivation results in an increase in p53 expression, Biol. Chem. Hoppe Seyler, 376:627.
95. Russo, T., Zambrano N., Esposito, F., Ammendola, R., Cimino, F., Fiscella, M., Jackman, J., O Connor, P.M., Anderson, C.W., and Appella, E., 1995, A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress, J. Biol. Chem. 270:29386.
96. Hainaut, P., and Milner, J., 1993, A structural role for metal ions in "wild-type" conformation of the tumor suppressor protein p53, Cancer Res. 53:1739.
97. Hainaut, P., Butcher, S., and Milner, J., 1995, Temperature sensitivity for conformation is an intrinsic property of wild-type p53, Br. J. Cancer, 71:227.
98. Sun, Y., Bian, J., Wang, Y., and Jacobs, C., 1997, Activation of p53 transcriptional activity by 1,10-phenanthroline, a metal chelator and redox sensitive compound, Oncogene 14:385.
99. Davidoff, A.M., Pence, J.C., Shorter, N.A., Ingelhart, J.D., and Marks, J.R., 1992, Expression of p53 in human neuroblastoma-and neuroepithelioma- derived cell lines, Oncogene 7:127.
100. Bi, S., Hughes, T., Bungey, J., Chase, A., de Fabritiis, P., and Goldman, J.A., 1992, p53 in chronic myeloid leukemia cell lines, Leukemia 6:839
101. Gao, J., Lovejoy, D., and Richardson, D.R., 1999, Effect of iron chelators with potent anti-proliferative activity on the expression of molecules involved in cell cycle progression and proliferation, Redox Report 4:311.
102. Linke, S.P., Clarkin, K.C., Di Leonardo, A., Tsou, A., and Wahl, G.M., 1996, A reversible, p53-dependent Go/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage, Genes and Develop. 10:934.
103. Levrero, M., De Laurenzi, V., Costanzo, A., Gong, J., Melino, G., and Wang, J.Y., 1999, Structure, function and regulation of p63 and p73, Cell Death Differ. 6:1146.
104. Lohrum, M.A., and Vousden, K.H., 2000, Regulation and function of the p53-related proteins: same family, different rules, Trends Cell Biol. 10:197.
105. De Laurenzi, V., Costanzo, A., Barcaroli, D., Terrinoni, A., Falco, M., Annicchiarico-Petruzzelli, M., Levrero, M., and Melino, O., 1998, Two new p73 splice variants, gamma and delta, with different transcriptional activity, J. Exp. Med. 188:1763.